Generic
Meningococcal group A Diphtheria Conjugate Vaccine
1 brands available in the market
At a glance
Meningococcal group A Diphtheria Conjugate Vaccine is used to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135. It is made by conjugating capsular polysaccharide antigens to diphtheria toxoid protein carrier.
Description
Meningococcal serogroup A, C, Y, and W-135 capsular polysaccharide antigens are individually conjugated to diphtheria toxoid protein carrier. This induces production of bactericidal antibodies directed against the capsular polysaccharides of serogroups A, C, Y, and W-135, providing protection from invasive meningococcal disease.
Indications
- Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135
- Immunization of high-risk adults and children
- Immunization of persons with asplenia or complement deficiencies
- Immunization of travelers to/residents in hyperendemic/epidemic countries
Therapeutic class
Vaccines, Anti-sera & Immunoglobulin
Pharmacological class
Conjugate Vaccine
Pharmacology
Meningococcal serogroup A, C, Y, and W-135 capsular polysaccharide antigens are conjugated to diphtheria toxoid protein. This induces production of bactericidal antibodies against serogroups A, C, Y, and W-135.
Mechanism of action
Induces production of bactericidal antibodies to protect against meningococcal infection.
Dosage
Adults and Adolescents:
- High-risk: 0.5 mL/dose IM as a single dose
- Asplenia/complement deficiencies: 2 doses (2 months apart), booster every 5 years
- Travel to hyperendemic countries: Single dose
Children:
- 11-12 years: 0.5 mL IM once; booster at age 16 years
- HIV infection: 2-dose primary series (8 weeks apart)
- 2-10 years: Single dose; 2nd dose for high-risk
- 2 months: 4-dose series (2, 4, 6, 12 months)
Administration
- IM injection only (do not give IV, SC, or ID)
- Anterolateral thigh in infants; deltoid muscle in toddlers, adolescents, and adults
Missed dose
Not generally applicable (vaccine); consult doctor if needed.
Side effects
Children (2 months, 4-dose series):
- Tenderness (24-41%), erythema (11-15%)
- Irritability (42-57%), sleepiness (29-50%)
- Persistent crying (21-41%), change in eating habits (17-23%)
- Vomiting (5-11%), diarrhea (8-16%)
Children (7-23 months, 2-dose series):
- Tenderness (10-16%), erythema (12-15%)
- Irritability (27-40%), sleepiness (17-29%)
Children (2-10 years): Injection site pain (31%), erythema (23%), irritability (18%), headache (11%)
Adolescents & Adults: Injection site pain (41%), headache (30%), myalgia (18%), nausea (10%)
Precautions & warnings
- Caution in Guillain-Barre syndrome
- Preventing and managing allergic vaccine reactions
- Caution in thrombocytopenia or bleeding disorders
- Caution in immunocompromised persons
- Caution in pregnancy and lactation
Contraindications
- Severe allergic reaction (e.g., anaphylaxis) after a previous dose, any component of this vaccine, or any other CRM197, diphtheria toxoid, or meningococcal-containing vaccine
Drug interactions
- Live vaccines
- Reduced immunological response with immunosuppressants
Food interactions
No food interactions applicable (injection).
Use in pregnancy
Use in Pregnancy: No adequate data; use only if clearly needed and benefits outweigh risks.
Use in lactation
Use in Lactation: No adequate data; administer when needed and benefits outweigh risks.
Pediatric use
Pediatric doses established for children 2 months to 18 years (age and risk-based).
Geriatric use
Doses established for adults.
Renal / hepatic impairment
May not induce effective response in immunocompromised individuals.
Overdose effects
Overdose not applicable (vaccine).
Storage conditions
Store in refrigerator (2-8°C); do not freeze; store in original package to protect from light; keep out of reach of children.
Chemical structure
Meningococcal group A Diphtheria Conjugate Vaccine